tbuckley/cabot-search huggingface dataset:
Neurodevelopmental Outcomes Following Surgical Ligation for Patent Ductus Arteriosus Among Extremely Preterm Infants
Authors: Elizabeth E. Foglia, Barbara Schmidt
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
CC-220 Is a Potent Cereblon Modulating Agent That Displays Anti-Proliferative, Pro-Apoptotic and Immunomodulatory Activity on Sensitive and Resistant Multiple Myeloma Cell Lines
Authors: Chad C Bjorklund, Jian Kang, Ling Lu, Michael Amatangelo, Hsiling Chiu, Anita K. Gandhi, Michael Pourdehnad, Anke Klippel, Anjan Thakurta
Journal: Blood (2016)
Peripheral Blood HPC Counts Are Augmented in CML Patients with Cytogenetic Findings of Disease as Compared to Patients in Cytogenetic Remission.
Authors: Ernesto de Meis, Rita C.B. Morais, Luize O. Carvalho, Arthur Moellmann-Coelho, Maria M.K. Martinez, Ana J.U.B. Costa, Ailce S. Barros, Ilda A.M. Castilho
Journal: Blood (2004)
Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation
Authors: Cynthia E. Fisher, Tobias M. Hohl, Wenhong Fan, Barry E. Storer, David M. Levine, Lu Ping Zhao, Paul J. Martin, Edus H. Warren, Michael Boeckh, John A. Hansen
Journal: Blood (2017)
CQC warns patients about buying medicines online
Authors: Anne Gulland
Journal: BMJ (2017)

Regulatory bodies have urged healthcare staff working for online primary medical providers to ensure they follow professional guidelines after two companies selling medicines online were found to have “widespread failings.”

The Care Quality Commission (CQC) suspended the registration of HR Healthcare—which traded as www.treated.com—after it found serious concerns over its practices. Another firm, MD Direct,—trading as www.assetchemist.co.uk—voluntarily cancelled its registration after the CQC raised similar concerns.

For both providers inspectors found there were no (or minimal) identity checks for patients; no way of identifying whether or not patients lacked capacity to consent or understand their prescribed treatment or medical advice; and no systems or processes to contact the patient’s …
The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice
Authors: Xiaojiaoyang Li, Runping Liu, Jing Yang, Lixin Sun, Luyong Zhang, Zhenzhou Jiang, Puneet Puri, Emily C. Gurley, Guanhua Lai, Yuping Tang, Zhiming Huang, William M. Pandak, Phillip B. Hylemon, Huiping Zhou
Journal: Hepatology (2017)

The multidrug resistance 2 knockout (Mdr2-/- ) mouse is a well-established model of cholestatic cholangiopathies. Female Mdr2-/- mice develop more severe hepatobiliary damage than male Mdr2-/- mice, which is correlated with a higher proportion of taurocholate in the bile. Although estrogen has been identified as an important player in intrahepatic cholestasis, the underlying molecular mechanisms of gender-based disparity of cholestatic injury remain unclear. The long noncoding RNA H19 is an imprinted, maternally expressed, and estrogen-targeted gene, which is significantly induced in human fibrotic/cirrhotic liver and bile duct-ligated mouse liver. However, whether aberrant expression of H19 accounts for gender-based disparity of cholestatic injury in Mdr2-/- mice remains unknown. The current study demonstrated that H19 was markedly induced (∼200-fold) in the livers of female Mdr2-/- mice at advanced stages of cholestasis (100 days old) but not in age-matched male Mdr2-/- mice. During the early stages of cholestasis, H19 expression was minimal. We further determined that hepatic H19 was mainly expressed in cholangiocytes, not hepatocytes. Both taurocholate and estrogen significantly activated the extracellular signal-regulated kinase 1/2 signaling pathway and induced H19 expression in cholangiocytes. Knocking down H19 not only significantly reduced taurocholate/estrogen-induced expression of fibrotic genes and sphingosine 1-phosphate receptor 2 in cholangiocytes but also markedly reduced cholestatic injury in female Mdr2-/- mice. Furthermore, expression of small heterodimer partner was substantially inhibited at advanced stages of liver fibrosis, which was reversed by H19 short hairpin RNA in female Mdr2-/- mice. Similar findings were obtained in human primary sclerosing cholangitis liver samples.H19 plays a critical role in the disease progression of cholestasis and represents a key factor that causes the gender disparity of cholestatic liver injury in Mdr2-/- mice. (Hepatology 2017;66:869-884).
Flow cytometric analysis of vesicular pH in rat hepatocytes after ethanol administration
Journal: Hepatology (1998)

In the article by Kharbanda et al. (Flow Cytometric Analysis of Vesicular pH in Rat Hepatocytes After Ethanol Administration'' Vol. 26, No. 4,, the second line in the legend to Figure 4 reads ''25 µmol/L ethanol.''The correct unit of measure is ''25 mmole/L ethanol.''
Pan-Histone Deacetylase (HDAC) Inhibitor LBH589 Depletes CXCR4 Levels and Signaling, Exerting Synergistic Anti-Leukemia Activity in Combination with CXCR4 Antagonists.
Authors: Aditya Mandawat, Warren Fiskus, Andrea Jakubowski, Rekha Rao, Zixuan Wang, Pravina Fernandez, Yongchao Wang, Pearl Lee, Anand Jillela, Peter Atadja, Nobutaka Fujii, Stephen C. Peiper, Kapil Bhalla
Journal: Blood (2007)
Noncoding Effects of Circular RNA CCDC66 Promote Colon Cancer Growth and Metastasis
Authors: Kuei-Yang Hsiao, Ya-Chi Lin, Sachin Kumar Gupta, Ning Chang, Laising Yen, H. Sunny Sun, Shaw-Jenq Tsai
Journal: Cancer Research (2017)

Circular RNA (circRNA) is a class of noncoding RNA whose functions remain mostly unknown. Recent studies indicate circRNA may be involved in disease pathogenesis, but direct evidence is scarce. Here, we characterize the functional role of a novel circRNA, circCCDC66, in colorectal cancer. RNA-Seq data from matched normal and tumor colon tissue samples identified numerous circRNAs specifically elevated in cancer cells, several of which were verified by quantitative RT-PCR. CircCCDC66 expression was elevated in polyps and colon cancer and was associated with poor prognosis. Gain-of-function and loss-of-function studies in colorectal cancer cell lines demonstrated that circCCDC66 controlled multiple pathological processes, including cell proliferation, migration, invasion, and anchorage-independent growth. In-depth characterization revealed that circCCDC66 exerts its function via regulation of a subset of oncogenes, and knockdown of circCCDC66 inhibited tumor growth and cancer invasion in xenograft and orthotopic mouse models, respectively. Taken together, these findings highlight a novel oncogenic function of circRNA in cancer progression and metastasis. Cancer Res; 77(9); 2339-50. ©2017 AACR.
Sixty seconds on . . . hospital bed numbers
Authors: Nigel Hawkes
Journal: BMJ (2017)

Both. The number of hospital beds (101 386) in the NHS in England is down this year, but that’s because two hospital trusts didn’t submit data. Correct for that, and there are around 700 more beds available this winter than last. However, over a decade the number fell by a fifth to 2.4 per 1000 population in 2015, the second lowest number …
Potential Role of ADAMTS13/FXI Complexes in the Pathogenesis of End Stage Renal Disease.
Authors: Jawed Fareed, D. Hoppensteadt, J. Cunanan, C. Patel, J. Maddineni, F. Baltasar, D. Fareed, M. Demir, M. Tobu, O. Iqbal, V. Bansal, R. Greenfield
Journal: Blood (2005)
Abstract P4-18-05: Male breast cancer— infusing a little blue into the sea of pink
Authors: H Wagner, J Boyages
Journal: Cancer Research (2017)

Abstract Male breast cancer (MBC) is a rare disease dominated by a sea of pink. Issues faced by men with this disease include delayed diagnosis, lack of male-specific information, stigma about having a "female disease" and often under-treatment. MBC is often treated as a female breast cancer but differences between the two are starting to emerge. Men are often older at diagnosis and sometimes considered "too old" for more aggressive treatments such as chemotherapy. Drugs such as aromatase inhibitors may not be as effective in men as in women but are often prescribed. Drugs such as tamoxifen can cause side-effects such as weight gain, hot flushes, loss of libido and impotence. Support for patients with MBC is less advanced than that for female breast cancer. A Man's Pink, a MBC advocacy organization, mission is to promote MBC awareness, increase early detection, optimize and increase the survival rates for men diagnosed with breast cancer. Male Breast Cancer: Taking Control (BC Publishing, Boyages, 2015) empowers patients to understand their diagnosis and treatment. Apart from incidence data, prognosis and treatment options, this talk will focus on how a website (www.malebreastcancer.ca) dedicated to MBC can help dismiss some of the myths and help overcome stigmata for men facing difficulties at diagnosis, treatment and recovery. Our goal is to promote awareness to assist with earlier diagnosis and treatment to improve survival rates and the journey for men in their battle with breast cancer. Citation Format: Wagner H, Boyages J. Male breast cancer— infusing a little blue into the sea of pink [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-18-05.
Multipotent Adult Progenitor Cells (MAPC) Are Immunoprivileged and Demonstrate Immunosuppressive Properties on Activated T Cell Population.
Authors: Magdalena Kovacsovics-Bankowski, Philip R. Streeter, Erin Hewett, Wouter J. Van’t Hof, Robert J. Deans, Richard T. Maziarz
Journal: Blood (2005)
Assessment of Insertional Mutagenesis Risk Following AAV Vector-Mediated Factor IX Gene Transfer in Mice.
Authors: Hojun Li, Nirav Malani, Shari R Hamilton, Alexander Schlachterman, Jim Z Zhang, Giulio Bussadori, Shyrie A Edmonson, Federico Mingozzi, J. Fraser Wright, Valder R. Arruda, Frederic D Bushman, Katherine A. High
Journal: Blood (2009)
Targeting Lymphoma By the Bi-Functional Hexameric Fusion Protein CTLA4-Fasl; Mode-of-Action, Pre-Clinical Efficacy and Toxicology Studies
Authors: Alexandra Aronin, Shira Amsili, Tatyana Prigozhina, Moshe Baru, Efi Makdasi, Kobi Tzdaka, Fanny Shkedy, Noam Shani, Michal Dranitzki Elhalel
Journal: Blood (2015)
Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls.
Authors: Kathy Pan, Rowan T. Chlebowski, Michael S. Simon, Roberta Ray, Jennifer Livaudais-Toman, Shannon D. Sullivan, Marcia L. Stefanick, Robert B. Wallace, Meryl LeBoff, Elizabeth C. Bluhm, Electra D. Paskett
Journal: Journal of Clinical Oncology (2015)

553 Background: While distinct health issues are associated with breast cancer and related therapies, comprehensive assessment of medication use before and after breast cancer diagnosis compared to age-matched, cancer-free controls has not been reported. Methods: From the 93,338 postmenopausal participants in the Women’s Health Initiative trials, medication inventories by pill container review were serially obtained before and > 3 years (mean 5.3 + 2.1 SD) after early stage breast cancer in 1730 cases matched with 1730 controls on age, dates of initial and follow-up medication inventories, body mass index, and smoking. Number of medications and medication classes (excluding tamoxifen and aromatase inhibitors [AI]) in cases and controls were compared. Results: Medication use (n) was comparable at baseline in both groups and significantly increased at follow-up in both cases (4.12 + 2.73 vs 6.47 + 3.29, P< .0001) and controls (3.92 + 2.59 vs 5.94 + 3.37, P < .0001), with clinically marginal but statistically significant additional medication use 0.53 ± 3.93 by breast cancer survivors (P < .0001). More breast cancer survivors used antidepressants (15.3% vs 12.2%, P = .006) and bisphosphonates and/or calcium/vitamin D (62.2% vs 54.8%, P < 0.001). Use of the following classes did not differ: anti-diabetic, cardiovascular, anti-anxiety, and narcotic and non-narcotic analgesics. Medication use at follow-up inventory by adjuvant endocrine therapy are outlined below. Medication use in breast cancer survivors on tamoxifen was lower than controls while those on AIs used more medications. Conclusions: Reflecting age-related co-morbidities, medication use significantly increases over time in both breast cancer survivors and controls. Overall, breast cancer impact on medication use is limited. Breast Cancer Cases (n=1730) Controls (n=1730) Selected medication classes (non-endocrine treatment) mean ± SD All Current Tamoxifen (n=426) Current AI (n=331) No Current Endocrine (n=975) 3.95 ± 2.13 (min=0, max=11) 4.15 ± 2.13 (min=0, max=11) 3.40 ± 1.89 (min=0, max=10), P=.05* 4.85 ± 2.10 (min=0, max=10). P=.002* 4.23 ± 2.14 (min=0, max=11) *Adjusted Poisson regression used for test of case-control differences.
Intramyocardial Injection of CD133+ Bone Marrow-Derived Stem Cells Improves Cardiac Function Long-Term in the Majority of Selected Patients with End-Stage Ischemic Heart Disease.
Authors: Marcus A. Stockschlaeder, Ali Ghodsizad, Volker Stoldt, Ludger Poll, Ruediger E. Scharf, Emmeran Gams, Michael Klein
Journal: Blood (2005)
Safety of catumaxomab: Cytokine-release-related symptoms as a possible predictive factor for efficacy in a pivotal phase II/III trial in malignant ascites
Authors: C. Bokemeyer, M. Heiss, H. Gamperl, R. Linke, E. Schulze, H. Friccius-Quecke, H. Lindhofer, S. Parsons
Journal: Journal of Clinical Oncology (2009)

3036 Background: As a targeted immunotherapy, the trifunctional antibody catumaxomab specifically binds to epithelial cell-adhesion molecule (EpCAM) on tumor cells and attracts T-cells via CD3 and accessory cells via its FcγRI/III+ region. The clinical relevance of this mode of action was demonstrated by Parsons et al. (ASCO 2008) in a pivotal phase II/III trial. Catumaxomab treatment resulted in a clinically relevant prolongation of puncture-free survival (defined as time to next puncture or time to death, which ever occurred first) in patients with malignant ascites. One of the most common adverse events associated with catumaxomab is cytokine-release-related-symptoms (CRRSs), which might be of predictive value for efficacy. Methods: The safety profile of catumaxomab was identified in the pivotal study. CRRSs (pyrexia, nausea, and vomiting) were among the most common adverse events in the catumaxomab group. A correlation between CRRSs and puncture-free survival, the primary endpoint, was performed to investigate whether patients who had CRRSs benefited from catumaxomab treatment more than those who had no CRRSs. Results: Among 157 patients, CRRSs were limited to the duration of catumaxomab treatment, with a median onset of 1 day after catumaxomab administration and a median duration of 1–2 days. Most of these symptoms were mild to moderate and were manageable by standard symptomatic treatment. Only 6 of 101 patients with CRRSs who were treated with concomitant medication required systemic corticoid therapy. Puncture-free survival was longer (48 days) in patients with (81%) CRRSs during catumaxomab treatment than in patients without (19%) CRRSs (27 days), although the difference was not statistically significant (p=0.1546, log rank test). Conclusions: CRRSs are a common occurrence with catumaxomab, due to its mode of action, during the treatment of patients with malignant ascites. Since CRRSs appear to be correlated with efficacy, they may therefore be a predictive factor for catumaxomab efficacy. [Table: see text]
Feasibility and safety of sequential research-related tumor core biopsies in clinical trials with anti-angiogenic and targeted therapies.
Authors: Jung-min Lee, John L. Hays, Anne M. Noonan, Jennifer Squires, Christina M. Annunziata, Bradford J Wood, Minshu Yu, Nicole D. Houston, Nilofer Saba Azad, Elise C. Kohn
Journal: Journal of Clinical Oncology (2012)

2545 Background: There has been increasing interest in serial/paired research biopsies (bx) in studies of molecularly targeted therapies. Definition of optimal target tissue and patient characteristics for safe and feasible research tumor bx in the era of anti-angiogenic and targeted therapies is needed. Methods: IRB-approved review of retrospective clinical data including patient demographics, pre-and post-procedure and recovery notes, and radiographic bx images. The cohort consisted of 142 pts scheduled for serial bx enrolled in phase 1 (5) and phase 2 (1) studies. Tumor core bx were obtained percutaneously under local anesthesia using a 16 or 18g needles under US or CT visualization by interventional radiologists. Results: Paired tumor core bx were collected in 96 pts (68%) and baseline only in 42 pts (32%). Bx were aborted in 4 pts due to cystic mass (3) and safety (1). 132 pts were female and 10 pts were male, median age 56 yrs (27-78), median BMI 25.8 (14.4-46.2), ECOG PS 0-2, and normal end-organ function. All pts had recurrent metastatic cancers (gynecologic 121, breast 6, sarcoma 5, melanoma 4, colon 2, adrenal 1, mesothelioma 1, RCC 1, papillary thyroid ca 1). 67 pts (51%) were on bevacizumab (bev)-based therapy at the time of their 2 nd /3 rd bx (bev + sorafenib; bev + dasatinib); others received gefitinib (27), imatinib (23), vandetinib (9), or olaparib + carboplatin (16). Median tumor size was 2.7cm (1-14.5cm). Bx sites were abd/pelvic masses 42, liver 40, lymph nodes 42, abd/chest wall 12, lung 4 (3 pleural, 1 parenchymal), and psoas muscle 1. Minor complications were observed in four pts (3%; uncomplicated liver subcapsular hematoma [1]; vasovagal syncope responding to fluids [2]; uncomplicated pneumothorax without intervention [1]) and there were no major complications. The median number of tumor cores was 3 (1-6) at the baseline, 2 nd (during or at the end of the first cycle) and 3 rd time point (during cycle 2). Conclusions: Core needle bx of deep internal lesions such as intra-abdominal masses and retroperitoneal lymph nodes can be obtained percutaneously under imaging guidance. Sequential tumor bx are feasible and safe for pts on anti-angiogenic and chemotherapeutic agents.
Is twice the duration of washout sufficient time between multiple breath nitrogen washout tests?
Authors: Elizabeth R. Salamon, Kevin R. Gain, Graham L. Hall
Journal: European Respiratory Journal (2017)

We read the paper by K.M. Hardaker and co-workers with great interest. Their study confirmed our earlier data: that a washout-derived wait time between measurements of nitrogen-based multiple breath washout (MBW) was not influenced by disease severity, and that on average a wait time of twice the duration of the washout between nitrogen MBW tests eliminated potential measurement artefacts [1]. Waiting for multiple breath washout: when is long enough? <http://ow.ly/5b5b306mYYh>
DYRK3 Encodes an Inhibitor of Erythroid Differentiation and Is Expressed at High Levels in Patients with Anemia.
Authors: David P. Steensma, Julie C. Porcher, Antony Chadderton, Kevin Laubscher, Deb Jaworski, Joanne J. Lager, William Bell, Bryan E. Hoffman, Connie L. Erickson-Miller
Journal: Blood (2007)
The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells
Authors: Mohanraj Ramachandran, Anna Dimberg, Magnus Essand
Journal: Seminars in Cancer Biology (2017)

Cell therapy is an advanced form of cancer immunotherapy that has had remarkable clinical progress in the past decade in the search for cure of cancer. Most success has been achieved for chimeric antigen receptor (CAR) T-cells where CAR T-cells targeting CD19 show very high complete response rates for patients with refractory acute B-cell acute lymphoblastic leukemia (ALL) and are close to approval for this indication. CD19 CAR T-cells are also effective against B-cell chronic lymphoblastic leukemia (CLL) and B-cell lymphomas. Although encouraging, CAR T-cells have not yet proven clinically effective for solid tumors. This is mainly due to the lack of specific and homogenously expressed targets to direct the T-cells against and a hostile immunosuppressive tumor microenvironment in solid tumors. Cancer vaccines based on dendritic cells (DC) are also making progress although clinical efficacy is still lacking. The likelihood of success is however increasing now when individual tumors can be sequences and patient-specific neoepitopes identified. Neoepitopes and/or neoantigens can then be included in patient-based DC vaccines. This review discusses recent advancements of DC vaccines and CAR T-cells with emphasis on the cancer-immunity cycle, and current efforts to design novel cell therapies.